Unlocking Disease Insights Through Glycoproteomic Quantitative Analysis
N-Glycoproteomics is the study of N-linked glycosylation, a crucial post-translational modification on proteins impacting their functions and cellular interactions. Aberrant N-glycosylation patterns are increasingly recognized as powerful indicators of various diseases, including diverse cancers, autoimmune disorders, acute infections, and cardiovascular conditions. Creative Biolabs leverages its cutting-edge analysis platforms to quantitatively analyze these changes, offering unparalleled insights for biomarker discovery, mechanistic understanding, and the development of targeted therapies. Our service is designed to unlock the full potential of this vital biological layer. Despite these challenges, providing this service is critical due to the limitations of conventional biomarker discovery and the unique insights glycans offer:
-
Addressing clinical needs: Many diseases, particularly cancers (e.g., early-stage HCC, GI cancers) and autoimmune disorders, lack sensitive, specific, and non-invasive biomarkers for early diagnosis, prognosis, and monitoring. Glycan alterations often precede or are more specific to disease states than changes in protein abundance alone.
-
Deeper mechanistic understanding: Glycosylation plays fundamental roles in cell-cell communication, protein folding, stability, and immune modulation. Quantitative glycoproteomics can reveal how these processes are dysregulated in disease, providing insights into pathogenesis.
-
Personalized medicine: Glycan signatures can vary between individuals and disease subtypes, offering the potential for personalized diagnostics and guiding tailored therapeutic strategies.
-
Drug target identification: Understanding altered glycosylation pathways or specific glycoforms reveals novel therapeutic targets for drug development.
Our Glycoproteomic Quantitative Analysis Service (such as N-glycan glycoproteomic, O-Glycan Glycoproteomic, Proteomic Analysis) helps you accelerate discovery, obtain precise molecular insights, and identify novel therapeutic targets through advanced mass spectrometry, multi-omics integration, and sophisticated bioinformatics.
Fig.1 Quantitative N-glycoproteomics analysis of plasma IgG in systemic sclerosis (SSc) patients.1,3
How Creative Biolabs' N-Glycan based Glycoproteomic Quantitative Analysis Service Can Assist Your Project?
At Creative Biolabs, our N-glycan glycoproteomic quantitative analysis service is meticulously designed to provide unparalleled insights into disease biology and therapeutic development. We deliver specific, actionable solutions by quantitatively profiling N-linked glycosylation changes on proteins, which are critical indicators of cellular health and disease states. Our service empowers clients to identify novel, highly specific biomarkers for early disease detection, accurately differentiate between similar conditions, monitor disease progression and treatment efficacy, and uncover new therapeutic targets by elucidating underlying molecular mechanisms. Our comprehensive workflow ensures robust and reliable results, guiding your project from initial concept to actionable data.
Our expert team collaborates with you to thoroughly understand your research goals, sample characteristics, and specific analysis requirements. We then design a tailored experimental plan, selecting the most appropriate quantitative strategy and glycopeptide enrichment methods to maximize data quality and relevance.
-
Sample Preparation & Glycopeptide Enrichment
This crucial stage involves meticulous processing of your biological samples. We perform depletion of high-abundance proteins (for plasma/serum), followed by multi-protease digestion (e.g., trypsin) to generate peptides. Subsequently, N-glycopeptides are selectively enriched using a combination of advanced techniques such as lectin affinity chromatography, hydrazide capture (for cis-diol-containing glycans), titanium dioxide (TiO2) chromatography (for sialic acid-containing glycans), hydrophilic interaction liquid chromatography (HILIC), etc.
Enriched glycopeptides are then precisely labeled using chosen quantitative methods (e.g., iTRAQ for multiplexing, or Dimethyl labeling for independent validation). These labeled glycopeptides are then analyzed using high-resolution liquid chromatography-mass spectrometry (LC-MS/MS) platforms. Our sophisticated instrumentation ensures accurate mass measurement and fragmentation for site-specific identification.
-
Glycoinformatics & Data Analysis
Raw mass spectrometry data undergo rigorous processing using specialized glycoinformatics software. We employ advanced statistical methods (e.g., Principal Component Analysis (PCA), Partial Least Squares-Discriminant Analysis (PLS-DA)) to identify differentially expressed glycopeptides/glycoproteins, build predictive models, and ensure robust data interpretation.
-
Biological Interpretation & Reporting
The quantitative data is translated into meaningful biological insights. Our team performs functional pathway analysis and correlates glycoproteomic changes with your provided clinical or experimental data. This step aims to elucidate the roles of altered glycoproteins in disease mechanisms.
We provide comprehensive N-glycoproteome profiles, quantitative abundance data, and biological insight reports. We list the identified N-glycoproteins and N-glycosylation sites in detail, and provide in-depth analysis of the functional significance of the observed glycoproteomic changes, including pathway enrichment, potential candidate biomarkers, and mechanistic hypotheses.
Why Choose Us?
Unparalleled Expertise and Rigor
With over years of experience in advanced biology and biochemistry, Creative Biolabs possesses deep scientific knowledge in glycomics and glycoproteomics. We implement rigorous quality control measures, ensuring the highest accuracy and reliability of your data.
Cutting-Edge Integrated Platforms
Our state-of-the-art mass spectrometry platforms are seamlessly combined with diverse glycopeptide enrichment strategies and advanced quantitative labeling, providing comprehensive and site-specific insights that other approaches miss.
Advanced Bioinformatics
Our strength lies not only in data generation but also in sophisticated data interpretation. We leverage advanced glycoinformatics software to extract meaningful biological insights, build robust predictive models, and differentiate complex disease states with high precision.
Related Services
To further support your research and development goals, Creative Biolabs provides a suite of complementary services that can be integrated with our N-glycan-based glycoproteomic quantitative analysis service:
-
Comprehensive Proteomics Services: Beyond glycoproteomics, we offer a full range of quantitative proteomics solutions.
-
Global Glycomics Profiling: For a broader understanding of the entire glycome, our glycomics service characterizes released N- and O-Glycans, providing insights into overall glycosylation patterns.
-
Custom Antibody Development: Develop highly specific antibodies targeting novel glyco-biomarkers identified through our services, crucial for diagnostic assay development.
At Creative Biolabs, we are committed to being your partner in scientific discovery, providing unparalleled N-glycan-based glycoproteomic quantitative analysis services and a comprehensive suite of complementary solutions. Our dedication to scientific excellence, cutting-edge technology, and client success ensures that your projects yield robust, actionable insights, driving forward advancements in precision medicine and therapeutic development. Ready to revolutionize your research with the power of glycoproteomics? Contact our expert team today to discuss your project, explore customized solutions, and receive a detailed quote.
Published Data
This study introduces a comprehensive multi-omics strategy that merges transcriptomics, glycomics, and glycoproteomics to thoroughly explore the molecular alterations linked to the development of hepatocellular carcinoma associated with hepatitis B virus (HBV-HCC). The study aimed to identify dysregulated glycoconjugates that could serve as potential diagnostic and prognostic biomarkers. A key part of this investigation involved a detailed quantitative glycoproteomic analysis of serum samples from healthy controls (HC), patients with chronic hepatitis B (CHB), those with liver cirrhosis (LC), and those with HBV-HCC. As depicted in Figure 2, the analysis began by identifying a large number of unique intact glycopeptides across these groups, with a significant overlap indicating common glycan modifications, but also unique peptides in each stage. The identified glycopeptides were then categorized by their N-glycan subtypes, revealing the prevalence of complex, hybrid, high mannose, and paucimannose structures. Further quantitative comparisons highlighted numerous glycopeptides that were differentially expressed when comparing disease states to healthy individuals, with specific thresholds applied for statistical significance. Among these altered glycopeptides, the study found that complex N-glycans were predominantly affected, with sialylated and fucosylated structures, along with bi-antennary configurations, being the most frequently observed modifications. These results collectively highlight the dynamic and distinct changes occurring in the glycoproteome throughout the progression of HBV-HCC, with a particular emphasis on the significance of fucosylation.
Fig.2 Results of quantitative N-glycoproteomic analysis of different serum samples.2,3
FAQs
Q1: How does Creative Biolabs ensure the accuracy and reliability of its glycoproteomic data?
A1: Creative Biolabs employs a multi-faceted approach to ensure data quality. This includes using multiple complementary glycopeptide enrichment strategies, state-of-the-art quantitative mass spectrometry, and rigorous bioinformatics pipelines with statistical validation. Crucially, we incorporate controls to differentiate in vivo deamidation from PNGase F-induced deamidation, preventing false-positive glycosylation site assignments and ensuring the highest data integrity.
Q2: How does N-glycan-based glycoproteomic quantitative analysis complement or differ from traditional proteomics?
A2: While traditional proteomics focuses on protein abundance, N-glycan-based glycoproteomics provides an additional, crucial layer of information: the specific sugar modifications on proteins and their attachment sites. These glycosylation changes are often highly dynamic and disease-specific, offering unique insights into protein functions, cellular interactions, and disease mechanisms that cannot be obtained from protein abundance alone. It acts as a powerful complementary approach for a more comprehensive biological understanding.
Q3: Can Creative Biolabs' service help with biomarker discovery for my specific disease of interest?
A3: Absolutely. Our service is designed for broad applicability in biomarker discovery across various therapeutic areas, including oncology, autoimmune diseases, infectious diseases, and cardiovascular conditions. We have a proven track record of identifying novel, highly specific glyco-biomarkers for early diagnosis, differential diagnosis, and disease monitoring. We encourage you to contact our team to discuss your specific project and how our expertise can accelerate your discovery efforts.
Customer Review
Unmatched Specificity
"Using Creative Biolabs's N-glycan-based glycoproteomic quantitative analysis service in our research has significantly improved our ability to identify highly specific N-glycan signatures for early cancer detection. Their results, particularly in serum samples, consistently outperformed traditional biomarkers like CA19-9, allowing us to pinpoint disease onset with unprecedented accuracy. Their attention to detail and rigorous data analysis are truly exceptional." - Mr. B. Jac***n.
Reliable Differential Diagnosis
"We faced significant challenges in differentiating bloodstream infections from other febrile conditions. Creative Biolabs's N-glycan-based glycoproteomic quantitative analysis service, applied to our liquid biopsy samples, provided clear and statistically significant separation between patient groups. Their robust analysis methods and thorough data interpretation were critical in validating these promising new diagnostic markers." - Prof. K. Whi***e.
References
-
Cheng, Lu, et al. "Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis." Frontiers in Immunology 16 (2025): 1531191. https://doi.org/10.3389/fimmu.2025.1531191.
-
Li, Zhuo, et al. "Integrating transcriptomics, glycomics and glycoproteomics to characterize hepatitis B virus-associated hepatocellular carcinoma." Cell Communication and Signaling 22.1 (2024): 200. https://doi.org/10.1186/s12964-024-01569-y.
-
Distributed under an Open Access license CC BY 4.0, without modification.
Related Services
For Research Use Only.
Contact Us
Follow us on
